Physician profile
Steven Degalan
NPI 1508849860
$16,140.66
in general payments reported to CMS, 2019-2025
39 companies · $1,773 in 2025
The $1,773 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,850 · 2020: $1,802 · 2021: $3,064 · 2022: $2,498 · 2023: $1,877 · 2024: $2,277 · 2025: $1,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,833 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,833.00 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $2,007.14 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $1,703.63 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,538.66 | 2019-2025 | Jardiance |
| Abbott Laboratories | $1,270.02 | 2019-2025 | Assurity, Gallant, Jot Dx |
| Janssen Pharmaceuticals, INC | $994.66 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $981.44 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $977.84 | 2019-2025 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $879.05 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $864.40 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $768.42 | 2019-2024 | |
| Novo Nordisk INC | $726.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $672.21 | 2019-2024 | Verquvo, Winrevair |
| Avanir Pharmaceuticals, INC. | $513.72 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $357.79 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $318.76 | 2019-2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Degalan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.